Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Liabilities and Shareholders Equity (2023 - 2025)

Metagenomi (MGX) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $221.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 31.88% to $221.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 29.99% year-over-year, with the annual reading at $221.1 million for FY2025, 31.88% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $221.1 million at Metagenomi, down from $247.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $415.4 million in Q1 2024, with the low at $221.1 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $320.9 million, with a median of $324.6 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity fell 11.03% in 2024, then tumbled 31.88% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $364.8 million in 2023, then fell by 11.03% to $324.6 million in 2024, then crashed by 31.88% to $221.1 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $221.1 million, $247.9 million, and $272.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.